Pramipexole Dihydrochloride

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended March 31, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates. “2026 is off to a strong start across our pipeline, highlighted by the initiation of the Phase 2b trial of ALTO-207 in TRD,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. “ALTO-207 is supported by one of the largest independently validated efficacy signals reported in TRD, and we believe the potentially registrational Phase 2b trial is designed to build on those results, and we are ahead of schedule on site initiations and patient recruitment. With $264 million on the balance sheet, Alto is well capitalized — with runway expected to extend through 2029 and, importantly, through a planned Phase 3 trial and potential NDA submission for ALTO-207.” Pipeline Highlights ALTO-207: Phase 2b trial in TRD initiated; potentially pivotal trial designed to replicate PAX-D antidepressant effects ALTO-207 is a fixed-dose combination of pramipexole, a dopamine D3-preferring D3/D2 agonist with demonstrated antidepressant effect, and ondansetron, a selective 5-HT3 receptor antagonist. The fixed-dose combination is designed to enable rapid titration to higher pramipexole doses by mitigating the dose-limiting nausea and vomiting historically associated with pramipexole. ALTO-207 is being developed to address the significant unmet medical need in TRD, which is estimated to affect up to 7 million adults in the United States. The core mechanism of ALTO-207 is supported by the PAX-D study, conducted by the University of Oxford and published in The Lancet Psychiatry, which demonstrated a Cohen’s d = 0.87 effect size for pramipexole versus placebo at 12 weeks — an effect more than two times larger than that observed for currently approved TRD therapies. A meta-analysis of pramipexole in depression has also reported a Hedges’ g = 0.64 (p < 0.001). In April 2026, Alto initiated a randomized, double-blind, placebo-controlled Phase 2b trial of ALTO-207 as an adjunctive treatment in approximately 178 adults with TRD who have experienced between two and five prior treatment failures and continue to have moderate-to-severe depression symptoms. The trial design and patient eligibility criteria build on the PAX-D study while employing MADRS as the primary endpoint, an approach aligned with FDA standards in depression and intended to support a streamlined registrational pathway. In January 2026, the U.S. Patent and Trademark Office issued U.S. Patent No. 12,521,374, a method-of-treatment patent specifically protecting the use of ondansetron to mitigate pramipexole-related side effects to enable higher pramipexole dosing for the treatment of depression. Together with Alto’s broader estate of issued and pending patents, the Company expects patent coverage of ALTO-207 through at least the mid-2040s. Alto remains on track to initiate a Phase 3 trial in TRD by early 2027, following alignment with the FDA on the planned trial design. ALTO-101: New analyses support biomarker hypothesis In April 2026, Alto reported topline results from the Phase 2 proof-of-concept (POC) trial of ALTO-101, a brain-penetrant PDE4 inhibitor evaluated as a transdermal formulation in cognitive impairment associated with schizophrenia (CIAS). The pre-specified primary analysis focused on electroencephalography (EEG) markers associated most strongly with CIAS. The trial did not achieve statistical significance on its primary CIAS EEG outcome, theta-band inter-trial coherence (or theta-ITC), though directional improvement was observed in this measure. Subsequent analyses focused on general EEG cognitive biomarkers, as well as exploratory analyses of cognitive test performance, yielding findings that suggest potential clinical effect of ALTO-101 in other cognitive disorders. In the overall study population (n = 83), ALTO-101 produced a Cohen’s d = 0.34 on theta-ITC versus placebo (p = 0.052). In a prespecified analysis of a more cognitively impaired subgroup (n = 59), ALTO-101 demonstrated a nominally significant effect on theta-ITC versus placebo (Cohen’s d = 0.44, p = 0.03). Alto views this signal as supportive of the relevance of theta-ITC as an objective EEG biomarker in CIAS and consistent with prior replicated analyses of large schizophrenia datasets. Further analyses identified large and statistically significant effects of ALTO-101 in the overall study population on multiple EEG markers relevant broadly to cognition. This included an increase in the individual alpha peak frequency (d=0.59, p=0.001), a robust and highly heritable index of an individual’s neurophysiological efficiency that tracks a range of cognitive functions. Analyses also revealed a shift to greater cortical excitability, as evidenced by an increase in high frequency power (beta: d=0.70, p<0.001; gamma: d=0.61, p=0.001) and decrease in low frequency power (theta: d=0.50, p=0.007). This resulted in a decrease in the theta/beta ratio (d=0.57, p=0.003), an FDA-cleared measure of attentional deficit/hyperactivity disorder that is likewise relevant to cognitive deficits in neurodegenerative disorders such as Parkinson’s and Alzheimer’s. Significant improvement was also observed with ALTO-101 in sustained attention, as measured by the Continuous Performance Task (d=0.41, p=0.02). No significant effects were observed in processing speed or memory. Alto has developed a modified-release, once-daily, well-tolerated oral formulation of ALTO-101 and the Company plans to explore partnering opportunities for this formulation. Enhanced eligibility review and patient quality measures implemented in ongoing Phase 2b trials for ALTO-300 and ALTO-100 Following the Company’s full analysis of its previously completed ALTO-100 MDD Phase 2b trial, Alto instituted an enhanced sponsor eligibility review process, site-level risk scoring, and certain new patient and data quality requirements into the ongoing Phase 2b trials for ALTO-300 in MDD and ALTO-100 in bipolar depression (BPD). The ongoing blinded data review supports the importance of these new enhanced procedures on the overall data quality in these trials. The Company believes the eligibility review process has resulted in a reduced risk of enrolling professional patients, a common risk across the field, with patients better reflecting the true treatment-seeking clinical population in the respective indications. Key metrics supporting the effectiveness of these efforts are as follows: In periodic batch testing of pharmacokinetic (PK) levels, 97% of samples demonstrated expected drug concentration levels. 100% of patients in the ALTO-300 MDD trial have demonstrated ongoing compliance with their underlying antidepressant as evaluated through urinalysis during trial conduct (the short half-life of ALTO-300 makes it undetectable in blood the day after dosing). In periodic batch testing of pharmacokinetic (PK) levels, 97% of samples demonstrated expected drug concentration levels. 100% of patients in the ALTO-300 MDD trial have demonstrated ongoing compliance with their underlying antidepressant as evaluated through urinalysis during trial conduct (the short half-life of ALTO-300 makes it undetectable in blood the day after dosing). 11% and 13% of patients have been screened out of the ALTO-100 and ALTO-300 trials, respectively, through Alto's sponsor eligibility review process – these represent patients who may have otherwise been included in the trial. Due to this new process, and the Company’s continued emphasis on patient quality, the topline data readouts are now expected in 1H 2027 for the ALTO-300 trial and mid-2027 for the ALTO-100 trial. These timing changes do not impact Alto’s overall cash runway guidance, and the Company still expects its existing cash to support planned operations through 2029. The company has incorporated these enrollment learnings into the ALTO-207 Phase 2b trial guidance and therefore does not expect these timing changes to impact the ALTO-207 Phase 2b readout timing, which is guided to 2H 2027. Corporate Updates In March 2026, the Company closed a private placement financing (“PIPE”) for gross proceeds of approximately $120 million led by Commodore Capital. In the PIPE, Alto sold an aggregate of 2,900,000 shares of its common stock at a price of $20 per share and, in lieu of common stock for certain investors, pre-funded warrants to purchase up to an aggregate of 3,100,000 shares of common stock at a purchase price of $19.9999 per pre-funded warrant. Together with existing cash, the proceeds from the PIPE are expected to support the development of ALTO-207 through a planned Phase 3 trial and to a potential NDA submission. Expected Upcoming Milestones Early 2027 — ALTO-207 Phase 3 TRD trial initiation 1H 2027 — ALTO-300 Phase 2b MDD trial topline data Mid 2027 — ALTO-100 Phase 2b BPD trial topline data 2H 2027 — ALTO-207 Phase 2b TRD trial topline data First Quarter 2026 Financial Highlights Cash Position: As of March 31, 2026, the Company had cash, cash equivalents, and restricted cash of approximately $264.2 million, compared to approximately $177.0 million as of December 31, 2025. The increase reflects net proceeds of approximately $115 million from the March 2026 PIPE, partially offset by cash used in operations during the quarter. The Company expects its cash balance to support planned operations — including the execution of the ALTO-207 Phase 2b trial, the planned ALTO-207 Phase 3 trial, and the ALTO-300 and ALTO-100 Phase 2b readouts — through 2029, including a potential NDA submission for ALTO-207. R&D Expenses: Research and development expenses for the quarter ended March 31, 2026, were $20.3 million, as compared to $10.0 million for the same period in 2025. G&A Expenses: General and administrative expenses for the quarter ended March 31, 2026, were $6.8 million, as compared to $5.7 million for the same period in 2025. Net Loss: The Company incurred a net loss of $26.2 million for the quarter ended March 31, 2026, as compared to a net loss of $15.2 million for the same period in 2025. About Alto Neuroscience Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in treatment-resistant depression, major depressive disorder, bipolar depression, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X. Forward-Looking Statements This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “look forward,” “may,” “on track,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Alto’s expectations with regard to the potential benefits, activity, effectiveness and safety of its product candidates and Precision Psychiatry Platform (“Platform”); statements regarding patient compliance and the effectiveness of Alto’s clinical trial execution measures, including its eligibility review and patient and data quality measures, and the impact of those measures on patient and data quality and the timing of trial readouts; statements regarding Alto’s expectations for the design, timing, and results of its Phase 2b and planned Phase 3 trials of ALTO-207; Alto’s expectations with regard to the design and results of its research and development programs and clinical trials, including the timing of enrollment and the timing and availability of data from such trials; Alto’s clinical and regulatory development plans for its product candidates, including the timing or likelihood of regulatory filings and approvals for its product candidates; Alto’s business strategy, financial position, including anticipated cash runway, and the sufficiency of its financial resources to fund its operations through expected milestones; and other statements that are not historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation, progress and completion of clinical trials and clinical development of Alto’s product candidates; the risk that Alto may not realize the intended benefits of its Platform or its eligibility review and patient and data quality measures; availability and timing of results from clinical trials; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that clinical trials may have unsatisfactory outcomes; the risk that Alto’s projections regarding its financial position and expected cash runway are inaccurate or that its conduct of its business requires more cash than anticipated; and other important factors, any of which could cause Alto’s actual results to differ from those contained in the forward-looking statements, which are described in greater detail in Alto’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and other filings Alto may make with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alto expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as required by law. Availability of Information on Alto’s Website Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website. ALTO NEUROSCIENCE, INC. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except per share amounts) (unaudited) Three months ended March 31, 2026 2025 Operating expenses: Research and development $ 20,294 $ 9,974 General and administrative 6,844 5,702 Total operating expenses 27,138 15,676 Loss from operations (27,138 ) (15,676 ) Other income (expense): Interest income 1,561 1,827 Interest expense (545 ) (598 ) Loss on debt extinguishment — (681 ) Other, net (115 ) (41 ) Total other income, net 901 507 Net loss $ (26,237 ) $ (15,169 ) Other comprehensive income (loss): Change in fair value attributable to instrument specific credit risk 7 134 Foreign currency translation (16 ) (19 ) Total other comprehensive income (loss) $ (9 ) $ 115 Comprehensive loss $ (26,246 ) $ (15,054 ) Net loss per share attributable to common stockholders, basic and diluted $ (0.80 ) $ (0.56 ) Weighted-average number of common shares outstanding, basic and diluted 32,893 27,049 ALTO NEUROSCIENCE, INC. Selected Condensed Consolidated Balance Sheet Data (in thousands) (unaudited) March 31, December 31, 2026 2025 Cash, cash equivalents, and restricted cash $ 264,262 $ 176,984 Total assets 276,259 184,689 Total liabilities 32,890 33,547 Accumulated deficit (227,871 ) (201,634 )

每年4月11日是世界帕金森病日，作为全球第二大神经退行性疾病，帕金森病正在影响着超过1000万人的生活。 据2025年发布的《中国帕金森病报告2025》显示，我国现存帕金森病患病人数已超过500万例，约占全球患病人数的43.14%，且患者数量还在以每年近10万的速度持续增长。 很多人对帕金森病的印象还停留在“手抖”，但实际上它是一种复杂的进行性疾病，不仅会剥夺患者的运动能力，还会带来一系列非运动症状。 虽然目前尚无根治方法，但近年来医学领域取得了突破性进展，从经典药物的优化到细胞疗法的问世，为患者带来了新的希望。 一、认识帕金森病：不止是“手抖”那么简单 帕金森病是一种主要影响中老年人的神经系统变性疾病，1817年由英国医师詹姆士·帕金森首次系统描述并因此得名。 其核心病理改变是 大脑黑质区域多巴胺能神经元 的进行性死亡，当这些神经元损失超过50%时，就会出现临床症状。 核心运动症状可以用“ 慢、僵、抖、倒 ”四个字概括： 运动迟缓 ：走路变慢、写字变小、穿衣吃饭等日常动作变得笨拙 肌强直 ：肌肉僵硬，活动时感到沉重、不灵活 静止性震颤 ：安静时手抖明显，活动时减轻或消失，典型表现为“搓丸样”动作 姿势平衡障碍 ：走路不稳、容易摔倒，晚期可能无法独立行走 更值得警惕的是非运动症状，它们往往在运动症状出现前数年就已存在，却容易被忽视： 嗅觉减退、长期便秘、睡眠障碍（尤其是梦中大喊大叫、拳打脚踢）、抑郁焦虑、认知下降 等。这些症状对患者生活质量的影响有时甚至超过运动症状。 二、目前临床常用药物：六大类各有千秋 药物治疗是帕金森病的首选和主要治疗手段，目标是改善症状、提高生活质量。目前临床上常用的药物主要分为六大类，它们通过不同机制补充多巴胺或增强其作用。 复方左旋多巴 ：治疗的“金标准” 复方左旋多巴至今仍是治疗帕金森病最基本、最有效的药物，对运动迟缓、肌强直的改善效果最为显著。它由左旋多巴和外周脱羧酶抑制剂（苄丝肼或卡比多巴）组成，后者能减少左旋多巴在外周的代谢，让更多药物进入大脑。 代表药物：多巴丝肼（美多芭）、卡左双多巴（息宁）、恩他卡朋双多巴。 临床要点：小剂量起始，空腹服用（餐前1小时或餐后1.5小时），避免与高蛋白食物同服。 长期使用（一般5年左右）可能会出现运动并发症，如剂末现象、开关现象和异动症，需要通过调整用药方案来控制。 2.多巴胺受体激动剂 ：早发型患者的优选 这类药物不直接补充多巴胺，而是模仿多巴胺的作用，直接激活大脑中的多巴胺受体。它们的作用更平稳持久，有助于推迟左旋多巴的使用和运动并发症的出现。 代表药物：普拉克索、罗匹尼罗、吡贝地尔，以及透皮给药的罗替高汀贴片。 临床要点：起始剂量要小，逐渐加量，避免出现体位性低血压和日间嗜睡。约15%的患者可能会出现冲动控制障碍，如病理性赌博、购物、暴饮暴食等，需要密切观察。 3. MAO-B抑制剂 ：早期单用，晚期辅助 这类药物通过抑制大脑中分解多巴胺的B型单胺氧化酶，延长多巴胺的作用时间。研究显示，它们可能具有一定的神经保护作用，能延缓疾病进展。 代表药物：司来吉兰、雷沙吉兰。 临床要点：司来吉兰应在早餐和午餐时服用，避免傍晚使用，以免引起失眠。司来吉兰严禁与5-羟色胺能药物（如SSRI类抗抑郁药）合用，否则可能引发危及生命的5-羟色胺综合征。 4. COMT抑制剂 ：延长左旋多巴的“有效期” 这类药物通过抑制儿茶酚-邻-甲基转移酶，减少左旋多巴在外周的代谢，从而增加进入大脑的药量，延长左旋多巴的作用时间，主要用于改善剂末现象。 代表药物：恩他卡朋、托卡朋。 临床要点：必须与左旋多巴同时服用，单独使用无效。常见不良反应有腹泻、尿色变黄。托卡朋可能会引起肝功能损害，需要定期监测肝功能。 5. 抗胆碱能药物 ：主要改善震颤 这类药物通过抑制大脑中乙酰胆碱的作用，恢复多巴胺和乙酰胆碱之间的平衡，对震颤的改善效果较好，但对运动迟缓、肌强直的效果较差。 代表药物：苯海索（安坦）。 临床要点：主要适用于震颤明显且年轻的患者。由于可能会导致认知功能下降，65岁以上或伴有智能减退的患者应尽量避免使用。闭角型青光眼和前列腺肥大患者禁用。 6.金刚烷胺 ：改善异动症的“多面手” 金刚烷胺最初是作为抗病毒药物开发的，后来发现它对帕金森病的强直、震颤、少动均有一定改善作用，尤其对左旋多巴引起的异动症效果较好。 临床要点：末次服药应在下午4点前，以免引起失眠。不良反应有下肢皮肤网状青斑、踝部水肿等，一般不严重，停药后可消失。 三、近五年新药速递：更安全、更方便、更有效 2021年至2026年5月，国内外有多款帕金森病新药获批上市，它们在疗效、安全性和给药方式上都有了显著提升，为患者提供了更多治疗选择。 甲磺酸沙非胺片：新一代MAO-B抑制剂 赞邦公司的甲磺酸沙非胺片（商品名：Xadago/悉达可）已在中国获批上市，用于治疗接受稳定剂量左旋多巴治疗的、出现运动波动的特发性帕金森病。 沙非胺是一款高度选择性、可逆的MAO-B抑制剂，与传统的司来吉兰和雷沙吉兰相比，它还具有额外的谷氨酸释放抑制作用，不仅能改善运动症状，还可能对非运动症状有一定益处。它的半衰期长，每天只需服用一次，依从性更好。中国Ⅲ期临床研究（XINDI研究）显示，在左旋多巴治疗基础上联合沙非胺，可显著缩短每日“关”期时间1.1小时，延长良好“开”期时间1.07小时，且安全性良好。 2.国产罗替高汀贴片：透皮给药新选择 2025年10月，四川科伦药业的罗替高汀贴片（商品名：艾罗星®）获国家药监局批准上市，成为国内首款获批的罗替高汀仿制药。 罗替高汀是一种非麦角类多巴胺受体激动剂，采用独特的透皮给药系统，绕过胃肠道吸收，实现24小时持续稳定的多巴胺能刺激。这种给药方式能显著减少血药浓度波动，有效预防和改善“开关现象”，特别适合有胃肠道问题或无法口服药物的患者。 3.奥吡卡朋：第三代COMT抑制剂 复星医药与Bial合作的奥吡卡朋胶囊是第三代COMT抑制剂，其上市申请已于2024年11月获国家药监局药品审评中心受理，预计2026年获批上市。 与第一代恩他卡朋相比，奥吡卡朋的半衰期更长，对COMT酶的抑制作用更强、更持久，每天只需服用一次，就能显著延长左旋多巴的“开期”时间，减少“关期”时间，且安全性更好。 四、未来可期：在研突破性疗法有望改写治疗格局 如果说传统药物和近年获批的新药主要是“对症治疗”，那么目前处于临床试验阶段的一系列突破性疗法，则有望从根本上改变帕金森病的治疗模式，实现“对因治疗”甚至“治愈”。 细胞疗法：最有希望的“治愈”方向 细胞疗法是目前帕金森病治疗领域最热门、最有前景的研究方向。它的原理是通过移植健康的多巴胺能神经元前体细胞，替代患者大脑中已经死亡的神经元，重建神经回路，从而从根本上恢复大脑的功能。 中国领跑全球： 睿健医药NouvNeu001：全球首个获FDA快速通道资格（FTD）和再生医学先进疗法认定（RMAT）双认定的iPSC帕金森细胞治疗产品。2026年3月已完成中国II期临床试验全部患者给药，2026年2月在美国完成II期临床首例患者给药。临床数据显示，给药后12个月，患者运动功能评分平均改善超过50%，且效果持续存在。 跃赛生物UX-DA001：全球首款中美双临床获批的自体干细胞疗法，2024年12月获国家药监局默示许可，2025年2月获美国FDA临床试验许可。2025年3月，上海瑞金医院完成首例患者移植，术后一年患者已能扔掉拐杖独立爬山。自体细胞疗法的最大优势是不会产生免疫排斥反应，患者无需服用免疫抑制剂。 士泽生物XS-411：通用型iPS衍生多巴胺能神经前体细胞注射液，2025年1月同步获得中国和美国FDA的临床试验批准。通用型细胞疗法可以实现“现货供应”，大大降低治疗成本和等待时间。2025年8月已完成中国首例患者给药。 国际巨头进展： 拜耳全资子公司BlueRock Therapeutics的bemdaneprocel（BRT-DA01）于2025年9月启动了全球首个帕金森干细胞疗法的关键III期临床试验exPDite-2，并完成首例患者给药，预计2028年完成试验。该疗法利用人多能胚胎干细胞分化为多巴胺能神经元前体细胞，通过手术植入患者大脑，旨在替代退变的神经元、重建神经功能。 基因疗法：从源头修复缺陷 基因疗法通过将正常基因导入患者大脑，修复导致多巴胺能神经元死亡的基因缺陷，或表达神经营养因子保护神经元。 目前，天泽云泰的VGN-R09b、瑞宏迪医药的RGL-193注射液等多款双基因疗法已在中国进入临床研究阶段，它们通过AAV载体递送，旨在同时增强脑内多巴胺合成并发挥神经保护作用。拜耳旗下AskBio公司的AB-1005基因疗法也已在欧洲开展II期临床试验。 新型小分子与生物制剂：瞄准疾病进展 除了细胞和基因疗法，还有多款针对新靶点的药物正在研发中： Tavapadon：全球首个D1/D5受体部分激动剂，与传统多巴胺激动剂主要靶向D2/D3受体不同，因此幻觉、冲动控制障碍等不良反应更少。艾伯维已于2025年9月向FDA提交上市申请，预计2026年获批。 普拉西珠单抗：全球首个靶向α-突触核蛋白的单克隆抗体，旨在清除大脑中异常聚集的α-突触核蛋白，真正延缓疾病进展。该药目前仍处于全球III期临床试验阶段，尚未在任何国家获批上市，预计2027年前后可能得出关键数据。 LRRK2抑制剂：针对LRRK2基因突变的帕金森病患者，渤健/Denali的BIIB122目前处于全球II期临床试验阶段。 五、写在最后：科学治疗，拥抱希望 帕金森病虽然目前还无法根治，但通过科学规范的治疗，绝大多数患者可以在很长一段时间内保持较好的生活质量。对于患者来说，最重要的是早发现、早诊断、早治疗，在专业医生的指导下制定个体化的治疗方案，并坚持长期随访和康复训练。 随着医学技术的飞速发展，我们正处于帕金森病治疗的革命性时代。细胞疗法、基因疗法等突破性技术的不断突破，让我们看到了“治愈”帕金森病的曙光。相信在不久的将来，帕金森病将不再是“不死的癌症”，而是一种可以被有效控制甚至治愈的疾病。